milataxel

Small moleculeexperimental

Milataxel is a taxol analog. — Wikipedia

Clinical trial activity

3 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 23, 2003 (NCT00063219)

Timeline

2000s

Jan 1, 2003
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C

Mol. weight: 852.93 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaMilataxel ↗
ChEMBLCHEMBL2107759 ↗

Also known as

5,20-epoxy-1,2,4,7,10,13-hexahydroxytax-11-en-9-one 4-aceetate 2-benzoate 7-propionate 13-ester with n-tert-butoxycarbonyl-3-(2-furyl)isoserine
5beta,20-epoxy-1,2alpha-,4-,7beta-,10beta-, 13alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate 7-propionate 13-ester,(2r,3s)-n-tertbutoxycarbonyl-3-(2-furyl)isoserine
mac321
mac 321
mac-321
mac-321
mac-321
milataxel
milataxel
milataxel
milataxel
milataxel
tl 139
tl-139
tl139 cpd

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00685204	Phase 2	Mar 1, 2008	New York University, Taxolog Inc.
NCT00063427	Phase 2	Jun 26, 2003	Pfizer, Wyeth
NCT00063219	Phase 2	Jun 23, 2003	Pfizer, Wyeth

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Pfizer	For profit	2	2	1	2003
Wyeth	For profit	2	0	1	2003
New York University	Academic/Hospital	1	0	1	2008
Taxolog Inc.	For profit	1	1	1	2008

4 organizations

Page 1 / 1